As a pioneer and the undisrupted global leader in antibody/functional peptide discovery, Creative Biolabs proudly introduces our professional discovery service of antibody/peptide targeting Toxoplasma. We are pleased to use our extensive experience and advanced platform to offer the best service to satisfy each demand from our customers.
Toxoplasmosis is one of the most prevalent parasitic infections caused by an obligate intracellular parasite Toxoplasma gondii. This parasite has a wide host range including human and almost all warm-blooded animals. The clinical complications of the disease, especially in immunocompromised patients emphasize the importance of accurately identifying the infection. In particular, early diagnosis is critical for the effective therapy of the disease. The important role of an accurate diagnosis for the clinical management of toxoplamososis is a public health concern.
Various methods have been established in laboratory diagnosis, among which the serological tests play a vital role in the diagnosis of both human and animal toxoplasmosis. However, the development of standard and reliable reagents for serodiagnosis specifically ELISA remains laborious and expensive. And insufficient accuracy of several serodiagnostic tests necessitates the exploration of alternative reagents to be used for diagnostic purposes in the progress of toxoplasmosis control. Recently, epitope-based antigen has emerged as alternative tools for achievement of highly sensitive and specific capture antigens. The rationale behind using of epitope-based antigen for improvement of toxoplasmosis serodiagnosis would prove highly beneficial to increase the sensitivity and specificity, and thus improve the standardization of the tests.
Creative Biolabs has developed an advanced AntInfect™ Platform to offer high-quality antibody/peptide discovery service for a range of targets. Lots of high-specificity and affinity antibodies have been wildly used for therapeutic and diagnostic purposes. Pilot researches indicate that anti-SAG1 peptide antibodies can inhibit the penetration of T. gondii tachyzoites into enterocyte cell lines. Therefore, surface protein SAG1 and Related Sequence family (SRS), SAG2 and SAG3 can be good targets for therapeutic antibody development.
The use of epitope-based antigen for the development of new diagnostic tests of various infections has shown encouraging results against various diseases. Functional peptides can be discovered by our high-quality epitope mapping service, which is supported by phage display technology and high-density peptide array technology. Then, functional peptides can be used for potential diagnostic antigen discovery for new diagnostic tests.
Creative Biolabs is a leading provider that focuses on developing anti-parasite biomolecular with high specificity and affinity for research, diagnostic and therapeutic purposes. Our highly experienced team are dedicated to assisting our clients in the discovery of antibody/peptide targeting Toxoplasma.
Please contact us for more information and a detailed quote.
Reference
